ARWR Arrowhead Pharmaceuticals Inc

$21.33

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops drugs for the treatment of intractable diseases in the United States. The company is headquartered in Pasadena, California.

Website: https://arrowheadpharma.com

Sector
TRADE & SERVICES
Industry
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
September
CIK
879407
Address
225 SOUTH LAKE AVENUE, SUITE 1050, PASADENA, CA, US
Valuation
Market Cap
$1.54B
P/E Ratio
nan
PEG Ratio
-1.32
Price to Book
29.35
Performance
EPS
$-5.15
Dividend Yield
—
Profit Margin
0.00%
ROE
-565.00%
Technicals
50D MA
$15.79
200D MA
$20.48
52W High
$30.41
52W Low
$9.57
Fundamentals
Shares Outstanding
137M
Target Price
$45.64
Beta
1.00

ARWR EPS Estimates vs Actual

● Estimated
● Actual

ARWR News & Sentiment

Aug 14, 2025 • Zacks Commentary NEUTRAL
Sarepta Sells Arrowhead Stake to Fund Milestone Payment
Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.
Aug 13, 2025 • CNBC NEUTRAL
Small caps rally as Magnificent 7 stocks roll over in market rotation
Investors rotated to small companies and turned away from megacap technology stocks that have led the market in recent years.
Aug 07, 2025 • Motley Fool SOMEWHAT-BULLISH
Arrowhead ( ARWR ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, August 7, 2025 at 8:30 p.m. ETPresident and Chief Executive Officer - Dr. Christopher AnzaloneContinue reading ...
Aug 07, 2025 • Motley Fool NEUTRAL
Arrowhead ( ARWR ) Q3 Revenue Drops 41%
Arrowhead Pharmaceuticals ( NASDAQ:ARWR ) , a biotechnology firm focused on developing RNA interference ( RNAi ) therapeutics, released its fiscal third-quarter earnings on August 7, 2025. The most notable news from the release was a substantial miss on both GAAP revenue and earnings for Q3 ...
Aug 07, 2025 • Zacks Commentary NEUTRAL
Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries
SRPT rallies after Q2 earnings and revenue beat expectations as Elevidys deliveries resume following FDA clearance.
Aug 04, 2025 • Zacks Commentary NEUTRAL
Sarepta to Report Q2 Earnings: What's in Store for the Stock?
SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.
Sentiment Snapshot

Average Sentiment Score:

0.108
50 articles with scored sentiment

Overall Sentiment:

Neutral

ARWR Reported Earnings

Feb 04, 2025
Dec 31, 2024 (Pre market)
-0.67 Surprise
  • Reported EPS: $-1.39
  • Estimate: $-0.72
  • Whisper: —
  • Surprise %: -92.2%
Nov 27, 2024
Sep 30, 2024 (Pre market)
-0.45 Surprise
  • Reported EPS: $-1.37
  • Estimate: $-0.92
  • Whisper: —
  • Surprise %: -48.6%
Aug 08, 2024
Jun 30, 2024 (Post market)
-0.83 Surprise
  • Reported EPS: $-1.38
  • Estimate: $-0.55
  • Whisper: —
  • Surprise %: -150.9%
May 09, 2024
Mar 31, 2024 (Post market)
-0.86 Surprise
  • Reported EPS: $-1.02
  • Estimate: $-0.16
  • Whisper: —
  • Surprise %: -537.5%
Feb 06, 2024
Dec 31, 2023 (Post market)
-0.42 Surprise
  • Reported EPS: $-1.24
  • Estimate: $-0.82
  • Whisper: —
  • Surprise %: -51.2%
Nov 29, 2023
Sep 30, 2023 (Post market)
-0.42 Surprise
  • Reported EPS: $-1.02
  • Estimate: $-0.60
  • Whisper: —
  • Surprise %: -70.0%
Aug 07, 2023
Jun 30, 2023 (Post market)
-0.31 Surprise
  • Reported EPS: $-0.96
  • Estimate: $-0.65
  • Whisper: —
  • Surprise %: -47.7%
May 02, 2023
Mar 31, 2023 (Post market)
1.09 Surprise
  • Reported EPS: $0.45
  • Estimate: $-0.64
  • Whisper: —
  • Surprise %: 170.3%
Feb 06, 2023
Dec 31, 2022 (Post market)
-0.83 Surprise
  • Reported EPS: $-0.39
  • Estimate: $0.44
  • Whisper: —
  • Surprise %: -188.6%

Financials